Organization
Pfizer Inc, Collegeville, PA, United States of America
4 abstracts
Abstract
AGE-BASED (<65 VS ≥65 YEARS) INCIDENCE OF INFECTIONS AND SERIOUS INFECTIONS IN TOFACITINIB-, ADALIMUMAB- AND PLACEBO-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, PHASE 3 AND PHASE 3B/4 TOFACITINIB STUDIESOrg: Pfizer Inc, Montreal, QC, Canada, Pfizer Inc, Sollentuna, Sweden, Pfizer Inc, Groton, CT, United States of America, Pfizer Inc, Peapack, NJ, United States of America, Pfizer Inc, Collegeville, PA, United States of America,
Abstract
ANALYSIS OF NON-MELANOMA SKIN CANCER ACROSS THE TOFACITINIB RHEUMATOID ARTHRITIS CLINICAL PROGRAMME Org: University of Alabama, Birmingham, United States, Seoul National University, Seoul, Korea, Republic Of, Dermatology and Laser Center of Maui, Maui, United States, University of Paris-Sud, Paris, France, Pfizer Inc, Groton, CT, United States of America,
Abstract
BASELINE DEMOGRAPHIC AND DISEASE-STATE VARIABLES THAT MAY PREDICT A BETTER RESPONSE TO ETANERCEPT IN SUBJECTS WITH ANKYLOSING SPONDYLITIS: ASCEND Org: VU University Medical Center, Amsterdam, Netherlands, Rheumazentrum Ruhrgebiet, Herne, Germany, Pfizer Inc, Collegeville, PA, United States of America,
Abstract
BASELINE PAIN SEVERITY AS A PREDICTOR OF PAIN IMPROVEMENT FOLLOWING TREATMENT WITH TOFACITINIB IN PSORIATIC ARTHRITISOrg: Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States of america, UZ Leuven, Leuven, Belgium, Pfizer Inc, Groton, CT, United States of America, Swedish Medical Center and University of Washington, Seattle, WA, United States of america, Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, United States of america,